PMAM
CRL icon

Picton Mahoney Asset Management’s Charles River Laboratories CRL Stock Holding History

Picton Mahoney Asset Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3M Buy
116,144
+20,748
+22% +$3.69M 0.19% 96
2026
Q1 		$16.5M Buy
95,396
+21,928
+30% +$4.07M 0.12% 157
2025
Q4 		$14.7M Sell
73,468
-4,841
-6% -$878K 0.11% 156
2025
Q3 		$12.3M Buy
78,309
+43,800
+127% +$6.96M 0.11% 167
2025
Q2 		$5.24M Buy
+34,509
New +$4.6M 0.05% 253
2024
Q1 		– Sell
-905
Closed -$213K – 404
2023
Q4 		$213K Buy
905
+230
+34% +$45.2K 0.01% 306
2023
Q3 		$132K Sell
675
-1,335
-66% -$274K ﹤0.01% 287
2023
Q2 		$423K Sell
2,010
-280
-12% -$55.7K 0.02% 257
2023
Q1 		$461K Buy
2,290
+647
+39% +$147K 0.02% 307
2022
Q4 		$358K Buy
1,643
+688
+72% +$150K 0.02% 418
2022
Q3 		$187K Sell
955
-14,430
-94% -$3.12M 0.01% 518
2022
Q2 		$3.29M Sell
15,385
-16,680
-52% -$4.08M 0.13% 223
2022
Q1 		$9.11M Sell
32,065
-3,505
-10% -$1.08M 0.32% 69
2021
Q4 		$13.4M Buy
35,570
+148
+0.4% +$57.5K 0.33% 38
2021
Q3 		$14.6M Sell
35,422
-800
-2% -$332K 0.54% 34
2021
Q2 		$13.4M Buy
36,222
+7,732
+27% +$2.58M 0.39% 51
2021
Q1 		$8.26M Sell
28,490
-1,075
-4% -$299K 0.39% 76
2020
Q4 		$7.39M Buy
29,565
+2,490
+9% +$593K 0.35% 87
2020
Q3 		$6.13M Buy
27,075
+18,675
+222% +$3.88M 0.34% 92
2020
Q2 		$1.46M Buy
+8,400
New +$1.34M 0.08% 198
2016
Q1 		– Sell
-14,700
Closed -$1.18M – 318
2015
Q4 		$1.18M Sell
14,700
-6,600
-31% -$476K 0.07% 158
2015
Q3 		$1.35M Sell
21,300
-25,200
-54% -$1.81M 0.08% 156
2015
Q2 		$3.27M Sell
46,500
-48,200
-51% -$3.57M 0.16% 116
2015
Q1 		$7.51M Buy
94,700
+66,600
+237% +$4.91M 0.29% 91
2014
Q4 		$1.79M Sell
28,100
-168,400
-86% -$10.6M 0.09% 141
2014
Q3 		$11.7M Buy
196,500
+76,800
+64% +$4.39M 0.63% 64
2014
Q2 		$6.41M Sell
119,700
-100
-0.1% -$5.49K 0.38% 90
2014
Q1 		$7.23M Buy
+119,800
New +$6.98M 0.42% 89

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Picton Mahoney Asset Management's CRL Position: Q2 2026 in Review

Picton Mahoney Asset Management increased its Charles River Laboratories (CRL) stake by 22% in Q2 2026, buying an estimated $3.69M and bringing the position to 116,144 shares worth $26.3M. The position accounts for 0.19% of the portfolio, ranked #96.

Picton Mahoney Asset Management first reported a position in CRL in Q1 2014 and has held it in 28 quarters since. 569 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Picton Mahoney Asset Management held 116,144 shares of Charles River Laboratories worth $26.3M as of Q2 2026.
  • Picton Mahoney Asset Management bought 20,748 Charles River Laboratories shares in Q2 2026, an estimated $3.69M.
  • Charles River Laboratories made up 0.19% of Picton Mahoney Asset Management's portfolio in Q2 2026, its #96 holding.
  • Picton Mahoney Asset Management first reported a position in Charles River Laboratories in Q1 2014 and has held it in 28 quarters since.
  • 569 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.